{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.0","upperLimit":"91.5","value":"68.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Disease-free Survival Rate (DFS) defined as the percentage of participants who were disease-free and alive at 3 years, counting the time from day 1 of treatment to time of disease recurrence or death, was calculated based on the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments\n\nDurvalumab: Durvalumab 1500mg IV every 3 weeks for 6 cycles\n\nIntensity Modulated Radiotherapy Treatments: Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks","id":"OG000","title":"Open-label, Single-arm"}],"paramType":"NUMBER","populationDescription":"Participants started to study treatment and treatment responses were assessed.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Disease-free Survival Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}